文献速递乳腺癌消化系统肿瘤

乳腺浸润性小叶癌的胚系致癌基因致病变异研究

Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast.
PubMed 文献 · J Clin Oncol · 2021-10-21

该研究纳入2,999例基于人群队列和3,796例临床多基因panel检测的乳腺浸润性小叶癌(ILC)女性,比较胚系致病变异(PV)频率。结果显示ILC中乳腺癌易感基因PV频率为临床队列6.5%、人群队列5.2%;CDH1和BRCA2 PV与ILC高风险相关(OR>4),CHEK2、ATM和PALB2 PV与中等风险相关(OR=2-4),BRCA1 PV无临床相关风险(OR<2)。与浸润性导管癌相比,CDH1 PV富集>10倍而BRCA1 PV显著减少。结论认为ATM、BRCA2、CDH1、CHEK2和PALB2 PV与ILC风险增加相关,但组织学不应影响基因检测决策。

要点

  • ILC中乳腺癌易感基因PV频率为临床队列6.5%、人群队列5.2%。
  • CDH1和BRCA2 PV与ILC高风险相关(OR>4),CHEK2、ATM、PALB2为中等风险(OR=2-4)。
  • BRCA1 PV与ILC无临床相关风险(OR<2),且较IDC显著减少。

核心结论

  • ATM、BRCA2、CDH1、CHEK2和PALB2的PV与ILC风险增加相关,而BRCA1 PV不增加ILC风险。
  • ILC与IDC总体PV频率相似,提示组织学不应影响基因检测决策。
  • 多基因panel检测可能适用于ILC女性,但CDH1应特别讨论因其低患病率和胃癌风险。

研究设计与样本

  • 研究纳入2,999例来自人群队列的ILC女性和3,796例接受临床多基因panel检测的ILC女性。
  • 比较ILC女性与未受影响女性对照之间、以及ILC与浸润性导管癌(IDC)之间乳腺癌易感基因胚系PV频率。
  • 检测基因包括ATM、BARD1、BRCA1、BRCA2、BRIP1、CDH1、CHEK2、PALB2、PTEN、RAD51C、RAD51D和TP53。

主要发现

  • ILC女性中乳腺癌易感基因PV频率在临床队列为6.5%,在人群队列为5.2%。
  • 病例对照分析显示CDH1和BRCA2 PV与ILC高风险相关(OR>4)。
  • CHEK2、ATM和PALB2 PV与ILC中等风险相关(OR=2-4)。
  • BRCA1 PV和CHEK2 p.Ile157Thr与ILC无临床相关风险(OR<2)。
  • 与IDC相比,CDH1 PV在ILC中富集>10倍,而BRCA1 PV在ILC中显著减少。

临床怎么用

  • ILC女性可考虑多基因panel检测,组织学类型不应成为拒绝基因检测的理由。
  • 检测前后应特别讨论CDH1基因,因其在ILC中富集且与胃癌风险相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the contribution of germline pathogenic variants (PVs) in hereditary cancer testing panel genes to invasive lobular carcinoma (ILC) of the breast. MATERIALS AND METHODS: The study included 2,999 women with ILC from a population-based cohort and 3,796 women with ILC undergoing clinical multigene panel testing (clinical cohort). Frequencies of germline PVs in breast cancer predisposition genes (ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, PALB2, PTEN, RAD51C, RAD51D, and TP53) were compared between women with ILC and unaffected female controls and between women with ILC and infiltrating ductal carcinoma (IDC). RESULTS: The frequency of PVs in breast cancer predisposition genes among women with ILC was 6.5% in the clinical cohort and 5.2% in the population-based cohort. In case-control analysis, CDH1 and BRCA2 PVs were associated with high risks of ILC (odds ratio [OR] > 4) and CHEK2, ATM, and PALB2 PVs were associated with moderate (OR = 2-4) risks. BRCA1 PVs and CHEK2 p.Ile157Thr were not associated with clinically relevant risks (OR < 2) of ILC. Compared with IDC, CDH1 PVs were > 10-fold enriched, whereas PVs in BRCA1 were substantially reduced in ILC. CONCLUSION: The study establishes that PVs in ATM, BRCA2, CDH1, CHEK2, and PALB2 are associated with an increased risk of ILC, whereas BRCA1 PVs are not. The similar overall PV frequencies for ILC and IDC suggest that cancer histology should not influence the decision to proceed with genetic testing. Similar to IDC, multigene panel testing may be appropriate for women with ILC, but CDH1 should be specifically discussed because of low prevalence and gastric cancer risk.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Yadav S, Hu C, Nathanson KL, et al. Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast. J Clin Oncol. 2021. PMID: 34672684. doi:10.1200/JCO.21.00640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。